Thomas Walz, PhD, is a Professor at The Rockefeller University and Head of the Laboratory of Molecular Electron Microscopy. Previously, he held positions as Assistant, Associate, and Professor at Harvard Medical School (1999–2015) and was an Investigator at the Howard Hughes Medical Institute (2008–2015). He earned his PhD and BS in biophysics from the University of Basel, Switzerland, and completed postdoctoral research at the University of Sheffield. Walz completed his education at the Biozentrum, University of Basel, Switzerland, where he received his Diploma in Biophysics (1992) and PhD in Biophysics (1996). He furthered his training as a postdoctoral researcher at the University of Sheffield (1996–1999). His research focuses on understanding membrane-related processes and the structural biology of membrane proteins in lipid environments. Utilizing cryo-electron microscopy and nanodisc technology, he investigates how lipid bilayers influence membrane protein structure and function. Key areas include mechanosensitive channels, T-cell receptor dynamics, and telomere maintenance mechanisms. Collaborations with the de Lange lab explore the CST-Polα/primase complex's role in telomere regulation. Walz has been recognized with the Genzyme Award for Outstanding Achievement in Biomedical Sciences (2004) and continues to contribute to advancements in structural biology and membrane protein research. While specific student advisees are not listed, Walz actively mentors through his roles in the David Rockefeller Graduate Program and Tri-Institutional programs. His research is supported by grants and institutional funding, though specific grants are not detailed here. He directs the Laboratory of Molecular Electron Microscopy at Rockefeller, a hub for innovative structural biology and membrane protein studies. The lab collaborates widely, integrating cryo-EM with electrophysiology and molecular dynamics simulations.
Sachdev Sidhu is a Research Professor and Entrepreneur in Residence at the University of Waterloo. His research focuses on synthetic antibodies, protein engineering, and biotechnological applications. He leads efforts in developing novel therapeutic antibodies, engineered protein systems, and molecular tools for biomedical research. His work spans cancer therapy, viral infection countermeasures, and regenerative medicine. Sidhu is also involved in translational research, bridging academic discoveries with commercial applications through entrepreneurial ventures. Key research interests include synthetic antibody libraries, CAR T-cell engineering, ubiquitin-based therapeutics, and phage display technologies. He has contributed to advancements in targeted therapies for glioblastoma, leukemia, and ocular diseases. His team develops innovative methods for protein design, such as engineered ubiquitin variants and modular antibody architectures. Publications highlight breakthroughs in antibody-based treatments, including synNotch CAR T cells for glioblastoma and neutralizing antibodies against SARS-CoV-2. His work integrates structural biology, molecular biology, and computational approaches to address complex biomedical challenges. Sidhu collaborates with industry partners to advance technologies into clinical and commercial settings.
Dr. Anil Kumar is an Assistant Professor in the Department of Biochemistry, Microbiology & Immunology at the University of Saskatchewan's College of Medicine. He specializes in molecular virology, focusing on positive-stranded RNA viruses and their interactions with host immune systems. His research employs high-throughput genetic screens and reverse genetics systems to identify host factors critical for viral infection. Education includes a BSc in Agricultural Sciences (1999, Kerala Agricultural University), MSc in Plant Pathology (2001, Indian Agricultural Research Institute), and PhD in Molecular Virology (2010, University of Heidelberg). Postdoctoral training included stints at the University of Heidelberg (2010–2013) and the University of Alberta (2014–2020). Research interests center on Eastern Equine Encephalitis virus (EEEV) and Enterovirus D68 (EV-D68). For EEEV, his lab investigates immune evasion mechanisms and host-virus protein interactions to identify therapeutic targets. For EV-D68, they study CNS invasion mechanisms and novel host dependency factors linked to acute flaccid myelitis (AFM). Recent work includes studies on SARS-CoV-2, uncovering roles for host proteins like Argonaute 2 in viral restriction. His lab integrates molecular biology, virology, and systems biology approaches, with a focus on translational research for antiviral drug development. Collaborations include work on respiratory syncytial virus (RSV) entry mechanisms and dengue virus replication regulation.
Prof. dr. Tessa Quax is an Associate Professor at the Faculty of Science and Engineering, University of Groningen, leading research in Molecular Microbiology . Her work focuses on archaeal virology and virus-host interactions, supported by prestigious grants including an ERC Starting Grant (2022) and NWO Vidi Grant (2023). Key Research Areas: Archaeal virus entry/egress mechanisms Cell surface dynamics and motility Extreme environment microbiology Genetic tool development for archaea Recent publications in Nature Reviews Microbiology (2025) and Current Opinion in Microbiology (2024) highlight her work on viral host recognition and structural diversity. Her lab's 44 research outputs span archaeal cell biology, viral evolution, and ecological impacts of virus-induced lysis. Scientific Recognition: KNAW Beijerinck Premium (2022) KNAW Early Career Award (2021) Hector Research Career Development Award (2021) ERC Starting Grant (2022) As Chair of the International Society for Viruses of Microbes SAB and Speaker of the German Microbiology Society's Microbial Viruses group, she coordinates global research networks including a HFSP grant (2023) with Japan/Australia/USA collaborators. Her lab currently includes PhD candidate Zaloa Aguirre Sourrouille and multiple postdoctoral researchers.
Hector Aguilar-Carreno is a Professor of Virology in the Department of Microbiology and Immunology at Cornell University's College of Veterinary Medicine, where he also serves as Associate Vice Provost in the Office of the Vice President for Research and Innovation. His research focuses on high-mortality paramyxoviruses including Nipah virus (NiV) and Hendra virus (HeV), as well as coronaviruses and other enveloped viruses. Dr. Aguilar-Carreno received his BS in Biochemical Engineering from Instituto Tecnologico de Tepic, Mexico, followed by an MS in Biology from California State University, Los Angeles, and a PhD in Biochemistry and Molecular Biology from the University of Southern California. He completed postdoctoral training in Virology at UCLA under Dr. Benhur Lee before becoming an Assistant Professor at Washington State University's Paul G. Allen School for Global Animal Health. His research spans four main areas: (1) Viral entry mechanisms, where his lab has identified novel domains in viral glycoproteins important for membrane fusion; (2) Viral egress, using multi-omics approaches to study viral assembly and budding; (3) Vaccine development using viral-like particles to generate neutralizing antibodies; and (4) Antiviral discovery targeting enveloped viruses. His lab employs innovative techniques including Flow Virometry and Raman Spectroscopy to study viral entry processes. Analysis of his recent publications reveals a strong focus on paramyxoviruses (particularly Nipah and Hendra viruses), coronavirus research, and the development of broad-spectrum antivirals. His work spans fundamental virology to translational applications, with numerous publications in high-impact journals including Nature, Science, and Cell Reports. President Elect of the American Society of Virology Chair of the American Society of Virology Diversity, Equity, and Inclusion committee Chair of the Cornell CVM Diversity Committee Director of the Cornell Program for Achieving Career Excellence Chair of 16 PhD student thesis committees Dr. Aguilar-Carreno has served on numerous scientific committees including the American Society for Virology Education Committee, the American Society of Microbiology Committee for Minority Education, and as a Standing Member of the VIR-A NIH study section. His leadership extends to chairing the Cornell CVM Diversity Committee and serving on the Cornell presidential postdoctoral fellowship committee, demonstrating significant commitment to diversity and mentorship in science.
Prof. Dr. Urs F. Greber is an Ordinary Professor of Molecular Cell Biology at the Department of Molecular Life Sciences, Faculty of Mathematics and Natural Sciences, University of Zurich. His research focuses on understanding how viruses interact with host cells, particularly adenoviruses and rhinoviruses that cause human respiratory diseases. He leads the Greber Lab, which investigates viral entry mechanisms, replication processes, and the cellular responses to infection. Greber's research interests span virology, molecular cell biology, and infection mechanisms. His lab explores how viruses take control over membrane and lipid functions, cytoplasmic transport processes, and cellular metabolism to support their gene expression and progeny formation. They employ system-wide profiling, molecular cell biology approaches, light microscopy, and machine learning for image analysis to map the cell state underlying viral infections of cultured and primary human cells, including lung organoids and iPSC-derived macrophages. A key focus is understanding cell-to-cell variability in infection phenotypes and the mode-of-action of antiviral compounds. The Greber Lab has published extensively on adenovirus biology, including viral entry, uncoating, nuclear import, and assembly mechanisms. Their recent work has identified broad-spectrum antiviral compounds, elucidated alternative virus entry pathways, and developed innovative imaging and AI-based approaches for quantifying virus infectivity. Their research contributes to understanding how viruses break down host defense barriers and has implications for antiviral therapy development. Greber has supervised numerous PhD and Master's students including Cornelia Bircher, Alessandro Savi, Franziska Tomas, Alfonso Gomez-Gonzalez, Anthony Petkidis, and Dominik Olszewski. His lab has received funding from the Swiss National Science Foundation, including a grant for coronavirus research during the pandemic. The lab actively collaborates with other research groups at University of Zurich, ETH Zurich, and international institutions. Current projects include exploring how viral DNA interactions contribute to infection outcome variability, investigating adenovirus egress mechanisms, and developing high-throughput screening methods for antiviral compounds.
Maartje Bastings is an Associate Professor at the École Polytechnique Fédérale de Lausanne (EPFL) , leading the Programmable Biomaterials Laboratory (PBL) within the School of Engineering (STI) . She holds additional affiliations with the Institute of Materials (IMX) , IBI-STI (Bioengineering), and supervises doctoral programs in Biotechnology and Biological Engineering ( EDBB-GE ) and Materials Science and Engineering ( EDMX-GE ). Her research focuses on DNA-based supramolecular materials engineered to achieve dynamic reciprocity —a two-way interaction between synthetic materials and biological systems. By leveraging DNA as a programmable scaffold, she investigates structural mechanics, valency control, and geometric constraints governing self-assembly and cell communication at bio-interfaces. Key applications include immune system modulation, diagnostics , and vaccine development . Analysis of her 15 most recent publications reveals a focus on multivalent interactions for T-cell activation, spatial patterning in immune signaling, and engineered coatings for DNA origami stability. Subfields span T cell receptor engineering , nanoscale protein dynamics , stimuli-responsive biomaterials , and bio-inspired therapeutic design . PhD Students: Chen Yuduo Hendrickx Pauline Bart M. Kononenko Artem Li Shujie Lou Yameng Meyer Pitt Narita Minako Rousseau Benjamin Bila Hale Caroprese Vincenzo Comberlato Alice Kurisinkal Eva Eugene Paloja Kaltrina Rodríguez Franco Hugo José Tekin Cem Wong Siu Ho Contact: maartje.bastings@epfl.ch
Professor Roland J. Pieters is a distinguished academic at Utrecht University's Faculty of Science, where he serves as a full Professor in the Department of Chemical Biology and Drug Discovery. With over two decades of experience at the institution, he has progressed from Assistant Professor (1998) to Associate Professor (2005) and ultimately to Full Professor (2010-present). His research group is internationally recognized for groundbreaking work at the intersection of carbohydrate chemistry, chemical biology, and drug discovery, with particular emphasis on developing novel therapeutic approaches against bacterial infections and pathogenic mechanisms. Full Professor, Utrecht University (2010-present) Associate Professor, Utrecht University (2005-2010) Assistant Professor, Utrecht University (1998-2005) NWO Talent Post-doctoral Fellow, ETH-Zürich (1995-1996) Postdoctoral Researcher, University of Groningen (1996-1998) Professor Pieters earned his M.Sc. in Organic Chemistry from the University of Groningen in 1990, where he worked with Professor Ben Feringa, and completed his Ph.D. at MIT in 1995 under the supervision of Professor Julius Rebek Jr. His doctoral research focused on molecular recognition and template effects in bisubstrate systems, establishing the foundation for his lifelong interest in molecular interactions. Professor Pieters' research primarily centers on glycodrugs and the strategic interference with protein-carbohydrate interactions using multivalent systems of varying architectures. His laboratory has made significant contributions to understanding how rigid spacers in multivalent ligands can dramatically enhance binding affinity to target proteins, with applications against viral and bacterial adhesion proteins, toxins, galectins, and glycosidases. A particular focus has been on developing inhibitors for Pseudomonas aeruginosa lectin LecA, cholera toxin, influenza virus hemagglutinin, and more recently, SARS-CoV-2 spike protein interactions with host cell receptors. His group also pioneered the use of glyco- and peptide-microarrays for high-throughput screening of carbohydrate-protein interactions and drug discovery, particularly in the area of O-GlcNAcylation research. The publication record of Professor Pieters demonstrates consistent innovation in the field of multivalent carbohydrate-based therapeutics. His recent work (2020-2024) shows a strategic expansion into viral pathogenesis (particularly influenza and SARS-CoV-2), immune modulation through glycan recognition, and novel approaches to vaccine development. A notable trend is the increasing sophistication of multivalent architectures, moving from simple divalent systems to tetra- and hexavalent ligands with precisely engineered spatial arrangements. His research bridges fundamental chemical principles with practical therapeutic applications, maintaining strong connections to pharmaceutical development while advancing basic science understanding of carbohydrate-mediated biological processes. Professor Pieters' scientific achievements have been recognized with prestigious awards including a Fellowship from the Royal Netherlands Academy of Arts and Sciences (KNAW) in 1999 and a VICI personal grant from the Netherlands Organisation for Scientific Research (NWO) in 2008. These competitive awards reflect the significance and innovation of his research program. He has also served on editorial advisory boards, notably as Section Editor-in-Chief for Chemical Biology in the journal Molecules (2018-2022), contributing to the scholarly community through peer review and academic leadership. Fellowship of Royal Netherlands Academy of Sciences (KNAW), 1999 VICI, personal grant, NWO, 2008 Section Editor-in-Chief Chemical Biology for Molecules (2018-2022) Throughout his career, Professor Pieters has coordinated significant research projects including the EU project POLYCARB and secured competitive funding that has sustained his innovative research program. His laboratory has fostered numerous collaborations across Europe and internationally, creating a vibrant research environment that has trained many scientists now working in academia and industry. His research on multivalent carbohydrate systems represents a sustained intellectual contribution to chemical biology with direct relevance to developing new anti-infective strategies and therapeutic approaches. Professor Pieters leads an active research group within Utrecht University's Department of Chemical Biology and Drug Discovery, situated in the David de Wied Building. His laboratory maintains strong connections with other research groups both within Utrecht University and internationally, particularly in the fields of glycobiology, infectious diseases, and drug discovery. The research environment he has cultivated emphasizes interdisciplinary approaches, combining synthetic chemistry, biophysical analysis, and biological testing to address fundamental questions in carbohydrate-mediated biological processes with therapeutic applications.
Prof. Wouter Roos is a Professor at the University of Groningen's Faculty of Science and Engineering, affiliated with the Molecular Biophysics department at the Zernike Institute for Advanced Materials. His research focuses on viral dynamics, membrane assemblies, and protein mechanics, utilizing advanced techniques like High Speed Atomic Force Microscopy (HS-AFM) and optical tweezers. Education: Studied Physics at the Universiteit van Amsterdam, earned a PhD from the Universität Heidelberg under Joachim Spatz. Conducted postdoctoral research at Max-Planck-Institut, Institut Curie, and Vrije Universiteit before joining Groningen in 2015. Research Interests: Physical Virology (viral material properties and dynamics), membrane biophysics (synthetic cells and lipid interactions), and molecular motor systems. His work bridges physics, chemistry, and biology to understand nanoscale biological processes. Recent Article Trends: Studies on hybrid membranes for synthetic cells, leukemic cell mechanics, and antibiotic-membrane interactions highlight his interdisciplinary approach. Key techniques include HS-AFM and single-particle tracking. Awards: Received a VIDI grant and multiple national/international grants. His lab leads the oLife Co-Fund consortium and participates in the MOSBRI research infrastructure. Grants & Leadership: Coordinates the oLife Fellowship Programme and chairs the Molecular Biophysics Lab. Active in steering committees for EU-funded initiatives. Labs/Teams: Heads the Molecular Biophysics Lab, focusing on viral dynamics and membrane systems. Collaborates globally on projects like ESCRT-III polymerization and antibiotic mechanisms.
Dr. Richard Y. Zhao is a tenured Professor in the Department of Pathology and Microbiology-Immunology at the University of Maryland School of Medicine. His research combines molecular biology, fission yeast genetics, mammalian biology, and virology to study virus-host interactions, particularly for HIV and Zika virus. He previously held academic positions at Northwestern University and Columbia University and has contributed to over 120 peer-reviewed articles. B.S., China Oceanography University (1981) M.S., Oregon State University (1995) Ph.D., Oregon State University (1991) Postdoctoral Training, Columbia University (1991-1992) Dr. Zhao's research focuses on: Virus-host interactions and pathogenicity High-throughput drug screening for antivirals Role of viral proteins in neuroinflammation and cancer Translational genomics in precision medicine His recent publications highlight SARS-CoV-2 ORF3a, Zika envelope proteins, and HIV protease inhibitors, emphasizing host-pathogen mechanisms across species. He has served on NIH panels and editorial boards for journals like Cell Research and Retrovirology . Scientific awards include: Fellow, American Academy of Microbiology (2019) Bernard L Mirkin Endowed Chair (2001-2004) Honorary Director, Shandong Gallo Institute (2009) Distinguished Service from SCBA (2015) Outstanding Service from CBA-USA (2016) Dr. Zhao also contributes to clinical diagnostics and personalized medicine through molecular testing and pharmacogenetics programs.
Gabriel Felbermayr is a Professor of Economics at Vienna University of Economics and Business (WU) and Director of the Austrian Institute of Economic Research (WIFO) since 2021. He holds a PhD in Economics and has held academic positions at the University of Munich (ifo Center for International Economics), Kiel University (Chair in Economics), and the University of Tübingen. University Professor: WU Vienna (2021–) Director: WIFO Vienna (2021–) President: Kiel Institute (2019–2021) Research Interests include international trade theory, labor markets in open economies, European integration, migration economics, and climate-trade intersections. His work combines theoretical models with empirical policy analysis, focusing on globalization challenges, supply chain disruptions, and economic sanctions. Current Projects Trump 2.0 Transatlantic Tariff Scenarios Scientific Awards include recognition for his research contributions, though specific award names are not detailed in the text. He has led major projects for institutions like the Austrian Economic Chamber and the Foundation for Family Businesses. Education includes studies at the University of Linz and University of Florence (PhD). His publications span journals like Journal of International Economics , Review of World Economics , and World Development .
Matti Sällberg is a Professor in Biomedical Analysis at Karolinska Institutet's Department of Laboratory Medicine, leading the VIVAC research group focused on vaccines and immunotherapies against viruses and cancer. He earned his DDS and PhD from Karolinska Institutet (1988-1992), followed by postdoctoral research at The Scripps Research Institute (1994-1996). As a leader in infectious disease and hepatology, his research addresses chronic viral hepatitis, cancer prevention, and gene/cell-based therapies (GTMPs/ATMPs). He has directed the Department of Laboratory Medicine (2011-2022) and actively teaches in biomedical laboratory science, dentistry, medicine, and nursing programs. Key research areas include SARS-CoV-2 vaccine development (OPENCORONA consortium), hepatitis B/D/C therapies, and Crimean-Congo hemorrhagic fever vaccines. His work combines basic science with translational efforts at Karolinska's ANA Futura facility. Notable projects include a phase I clinical trial for a broad-acting SARS-CoV vaccine and preclinical testing of hepatitis therapies. Collaborations span academia and industry, with funding from the Swedish Cancer Society, EU, and VINNOVA. He oversees advanced techniques like viral propagation, flow cytometry, and adoptive cell therapy manufacturing. Grants include a 2024 Swedish Cancer Society award for hepatitis-related cancer therapies and a 2022 Swedish Research Council grant for the Doctoral Program in Advanced Therapies. His team maintains an active lab with researchers like Lars Frelin and Gustaf Ahlén. Future work emphasizes expanding vaccine platforms against emerging pathogens and optimizing immuno-therapies for solid tumors.
Frank Heinrich serves as an Associate Research Professor in the Department of Physics at Carnegie Mellon University's Mellon College of Science, while maintaining a significant research presence at the National Institute of Standards and Technology (NIST) Center for Neutron Research in Gaithersburg, Maryland. His dual appointment reflects his interdisciplinary work bridging academic research and national laboratory resources, focusing on advanced biophysical techniques for studying membrane-associated biological processes. Dr. Heinrich earned his Ph.D. in Nuclear Physics from the University of Leipzig, Germany in 2005, followed by postdoctoral research at Johns Hopkins University and Carnegie Mellon University. His academic trajectory shows steady progression from Research Physicist (2008-11) to Assistant Research Professor (2011-16) and finally to his current position as Associate Research Professor (2016-present), while simultaneously maintaining his role as a Staff Scientist at NIST since 2008. His research centers on the structure of disease-relevant proteins, peptides, and small molecules at lipid membranes, with particular interest in the structural foundations of cell signaling in cancer. Heinrich employs a broad range of surface-sensitive techniques including electrical impedance spectroscopy, surface plasmon resonance, and neutron reflectometry. His work contributes significantly to developing future-generation neutron scattering instrumentation for soft-matter and biological research, making these advanced techniques accessible to both academic and industrial scientists. Analysis of his 15 most recent publications reveals a consistent focus on membrane-protein interactions, particularly examining KRAS signaling in cancer, antimicrobial peptides, and membrane-associated processes in neurodegenerative diseases. His work demonstrates sophisticated integration of experimental biophysics with computational approaches, often utilizing neutron scattering techniques to provide structural insights that other methods cannot achieve. As part of the Lösche/Heinrich Group within the Supramolecular Structures Lab, he collaborates extensively with Mathias Lösche and contributes to the joint UPSM-CMU MBSB graduate program. His research has practical implications for understanding cancer mechanisms, developing new antimicrobial strategies, and advancing biophysical instrumentation.
Pilar Pérez Romero is an Associate Professor in the Department of Biological Sciences at the University of Notre Dame, where she leads research on human cytomegalovirus (CMV) and host immune interactions. She has previously held academic positions at the National Centre for Microbiology in Madrid and the Biomedical Institute of Seville, Spain. Her research interests include: Virology and molecular mechanisms of CMV infection Virus-host interactions and immune evasion CMV-specific T-cell and neutralizing antibody responses Immunotherapy and vaccine design for CMV Applications in solid organ transplant recipients and congenital infection Her recent publications show a strong focus on CMV immunopathogenesis, with increasing emphasis on translational applications such as monoclonal antibody therapies, adoptive T-cell transfer, and vaccine development. She frequently employs transcriptomic and proteomic methods and collaborates on clinical studies involving transplant patients. Her scientific contributions include: Characterization of CMV antigens inducing protective immunity Identification of novel viral gene products involved in immune regulation Development of methods for CMV gene deletion and functional studies Contributions to clinical guidelines for CMV management in transplantation Dr. Pérez Romero advises research students and collaborates with multidisciplinary teams, including immunologists, virologists, and clinicians. Her work is supported by institutional and collaborative research funding, with potential applications in antiviral therapies and vaccinology. She leads a research laboratory focused on viral immunology and pathogenesis at Notre Dame.
Lars Frelin is an Associate Professor in Virology at Karolinska Institutet, where he also serves as Programme Director for the Study Programme in Biomedical Laboratory Science and the Master Programme in Diagnostic Cytology. He is the Facility Manager for ANA Futura and a member of the VIVAC (Vaccines and Immunotherapies against Viruses And Cancer) research group led by Matti Sällberg at the Department of Laboratory Medicine, Division of Clinical Microbiology. Dr. Frelin's academic background includes: PhD from Karolinska Institutet (2004) Docent (Associate Professor) in Virology, Karolinska Institutet (2013) His research focuses on vaccine development against infectious diseases, particularly hepatitis viruses. Working with the VIVAC research group, he investigates novel immunotherapeutic approaches to combat viral hepatitis B, C, and D. His work spans from basic virology to translational research, with an emphasis on understanding viral immune evasion strategies and developing therapeutic vaccines that can overcome immune tolerance in chronic infections. Dr. Frelin's scientific contributions span over two decades, with recent work focusing on universal coronavirus vaccines, novel prime-boost strategies for hepatitis viruses, and understanding the immune response to viral infections. His research demonstrates a consistent trajectory toward developing immunotherapies that target viral entry mechanisms and enhance host immune responses against persistent viral infections. Dr. Frelin has secured multiple research grants from the Swedish Research Council, including: "Pathogenesis and immune evasion strategies of hepatitis viruses: New transgenic mouse models and new therapies" (2020-2022) "Pathogenesis and immune evasion strategies of hepatitis viruses: New transgenic mouse models and new therapies" (2017-2019) "Understanding the hepatitis C virus nonstructural 5A protein: A new target for antiviral therapies" (2012-2014) As Programme Director, he oversees academic programs in Biomedical Laboratory Science and Diagnostic Cytology, shaping the education of future laboratory medicine professionals. His leadership extends to serving on the Infrastructure Committee at Karolinska Institutet (2016-2019, 2019-2022) and managing the ANA Futura facility since 2020. Dr. Frelin is an active member of the VIVAC research group, which focuses on developing vaccines and immunotherapies against viruses and cancer. The group employs various approaches including DNA vaccine technology, viral vector systems, and novel delivery methods to enhance immune responses against challenging viral targets.
